Imexpharm

Imexpharm ROE

The Return on Equity (ROE) of Imexpharm (IMP.VN) as of Oct 27, 2026 is 15.14 %. In the previous year, Return on Equity (ROE) was 14.70 % — a change of 2.99% (higher).

ROE

15.14 %

YoY

2.99%

Last updated:

In 2025, Imexpharm's return on equity (ROE) was 15.14 %, a 2.99% increase from the 14.70 % ROE in the previous year.

The Imexpharm ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
8.11 VND
Jan 1, 2019
10.42 VND
Jan 1, 2020
12.12 VND
Jan 1, 2021
10.54 VND
Jan 1, 2022
11.80 VND
Jan 1, 2023
14.37 VND
Jan 1, 2024
14.70 VND
Jan 1, 2025
15.14 VND
The Imexpharm ROE history
YEARROEYoY
15.14 %+2.99%
14.70 %+2.28%
14.37 %+21.78%
11.80 %+11.97%
10.54 %-13.04%
12.12 %+16.33%
10.42 %+28.43%
8.11 %+9.58%
7.40 %-21.29%
9.40 %+7.98%
8.71 %-19.12%
10.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

ROE Details

Decoding Imexpharm's Return on Equity (ROE)

Imexpharm's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Imexpharm's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Imexpharm's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Imexpharm’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Imexpharm stock

Return on Equity (ROE) of Imexpharm is 15.14 % in 2025.

Return on Equity (ROE) of Imexpharm changed from 14.70 % to 15.14 %, representing a 2.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Imexpharm since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Imexpharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Imexpharm

All Key Metrics — Imexpharm